Switch to:
More From Other Websites
The Quest for an Effective Treatment for Pancreatic Cancer Jun 22 2016
ETF’s with exposure to Halozyme Therapeutics, Inc. : June 10, 2016 Jun 10 2016
Halozyme Announces Agreement To Refinance Debt, Increases 2016 Guidance For Year-End Cash Balance Jun 08 2016
HALOZYME THERAPEUTICS INC Files SEC form 8-K, Entry into a Material Definitive Agreement,... Jun 08 2016
Halozyme Announces Agreement To Refinance Debt, Increases 2016 Guidance For Year-End Cash Balance Jun 08 2016
Halozyme Therapeutics, Inc. breached its 50 day moving average in a Bearish Manner : HALO-US : June... Jun 06 2016
Halozyme Presents Stage One Efficacy And Safety Analysis Of Phase 2 Clinical Study In Metastatic... Jun 04 2016
Halozyme Presents Stage One Efficacy And Safety Analysis Of Phase 2 Clinical Study In Metastatic... Jun 04 2016
Halozyme Therapeutics, Inc. breached its 50 day moving average in a Bullish Manner : HALO-US : May... May 26 2016
HALOZYME THERAPEUTICS INC Financials May 18 2016
Halozyme Therapeutics To Present At The UBS 2016 Global Health Care Conference May 17 2016
Halozyme Therapeutics To Present At The UBS 2016 Global Health Care Conference May 17 2016
Halozyme Therapeutics, Inc. :HALO-US: Earnings Analysis: Q1, 2016 By the Numbers May 12 2016
Edited Transcript of HALO earnings conference call or presentation 9-May-16 8:30pm GMT May 09 2016
HALOZYME THERAPEUTICS INC Files SEC form 8-K, Results of Operations and Financial Condition May 09 2016
Halozyme Therapeutics reports 1Q loss May 09 2016
Halozyme Therapeutics reports 1Q loss May 09 2016
Halozyme Reports First Quarter 2016 Financial Results May 09 2016
Halozyme Reports First Quarter 2016 Financial Results May 09 2016


Add Notes, Comments

If you want to ask a question or report a bug, please create a support ticket.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK